Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAIL66 + Tocilizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAIL66 | SAIL 66|SAIL-66 | CLDN6 Antibody 8 TNFRSF9 Antibody 32 | SAIL66 is a T-cell engager that targets CLDN6 on cancer cells and also binds to CD3 and TNFRSF9 (CD137), potentially inducing T-cell activation, cytokine release, and antitumor immune activity (J Immunother Cancer 2023;11(Suppl 1):1172). | |
Tocilizumab | Actemra | Atlizumab | Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05735366 | Phase I | SAIL66 + Tocilizumab | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |